Sciety's Product Videos
Sciety's Products & Differentiators
A full-suite service to raise equity funding.
Expert Collections containing Sciety
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Sciety is included in 2 Expert Collections, including Wealth Tech.
Companies and startups in this collection digitize & streamline the delivery of wealth management. Included: Startups that offer technology-enabled tools for active and passive wealth management for retail investors and advisors.
Excludes US-based companies
Latest Sciety News
Nov 9, 2023
NEOGAP Therapeutics AB Thu, Nov 09, 2023 07:45 CET The Swedish biotechnology company Neogap Therapeutics announces that the company has raised SEK 54 million in a new share issue and has also been granted an additional SEK 29 million in innovation funding from the EU. The total capital injection will be allocated to the company's ongoing clinical phase I/II study of patients with colorectal cancer and preparations for the subsequent study. Neogap Therapeutics, a company developing cell therapy for personalised cancer treatment, has strengthened its financial position through a new share issue of SEK 54 million, before issue costs, with the investment company Sciety and investment syndicate Sciety Venture Partners. Alongside this, the company has received a grant of just over SEK 29 million from the European Innovation Council (EIC) Accelerator, a part of the EU's Horizon Europe program. The positive comments from the EIC Accelerator evaluation notably underscore the unique nature and potential of Neogap's treatment: "Neogap has a unique approach to a complete individualised therapy that unlike any other current therapies has curative potential in many types of solid cancer with low risk of serious side effects." “These capital injections are a clear endorsement of the innovative spirit and dedicated team efforts that define Neogap's work. The EU funding confirms our ambition to be a driving force in the field of cancer therapy. With these resources, we can continue our development work as planned, bringing us closer to our long-term objective – to improve treatment and increase survival for cancer patients," says Samuel Svensson, CEO of Neogap. “We are delighted to once again invest in Neogap and thus be able to contribute to important advances in cancer treatment. The company has a unique approach that is based on the realisation that each cancer is unique and differs between different patients and tumours. By using proprietary algorithms for machine learning and patented technology to train the patient's own T-cells to attack the cancer cells, the company develops a completely individualised treatment,” says Andreas Lindblom, Managing Partner at Sciety. Neogap's personalised immunotherapy has the potential to tackle a variety of cancer types, with a primary focus on colorectal cancer, which accounts for approximately 10% of all cancer cases and is the second leading cause of death due to cancer. Leveraging its technologies, PIOR® and EpiTCer®, Neogap is developing personalised therapy strategies for each patient. This bespoke and targeted approach ensures that the therapy selectively attacks cancer cells and minimises impact on healthy tissue, which in turn contributes to a low risk of side effects. Neogap's ongoing phase I/II study primarily aims to demonstrate the treatment's safety, but the company will also explore signs of treatment efficacy, including measurement of tumour growth. For more information, please contact: Samuel Svensson, CEO About Neogap Therapeutics Neogap Therapeutics is a Swedish clinical-stage biotechnology company focused on developing personalised cancer immunotherapy using the patient's own cells. The therapy is based on the company's two technologies PIOR® and EpiTCer®. PIOR® is sophisticated software that uses DNA sequencing data from the patient and machine learning algorithms to select tumour-specific mutations. Following this, EpiTCer® is used to multiply T cells that can recognize and attack the selected tumor-specific targets. Neogap is located at Cancer Center Karolinska in Stockholm. To learn more about Neogap and its cutting-edge research, please visit the company's website at neogap.se and follow Neogap on LinkedIn . Tags:
Sciety Frequently Asked Questions (FAQ)
Where is Sciety's headquarters?
Sciety's headquarters is located at Grev Turegatan 26, Stockholm.
What is Sciety's latest funding round?
Sciety's latest funding round is Seed VC.
How much did Sciety raise?
Sciety raised a total of $1.2M.
Who are the investors of Sciety?
Investors of Sciety include Linc Invest and Erik Hjelmstedt.
Who are Sciety's competitors?
Competitors of Sciety include Abingworth and 7 more.
What products does Sciety offer?
Sciety's products include Funding and 1 more.
Who are Sciety's customers?
Customers of Sciety include Synartro, Saga Diagnostics, Cartana and Elypta.
Compare Sciety to Competitors
Medilink UK is a membership-based professional association and consulting firm that focuses on life science company growth. It uses the combined strengths of its regional partners to assist the growth and development of the life sciences commercial, academic, and clinical communities across the UK. It provides services to the medical device, pharmaceutical, and biotechnology industries. It was founded in 2005 and is based in Nottingham, United Kingdom.
LucyJRobertshaw (LJR) provides international business development consultancy services. It specializes in providing consultancy services to businesses within the Anglo-Nordic life sciences sectors. It was founded in 2012. It is based in Stockholm, Sweden.
Abingworth is an international investment group focused exclusively on the life sciences and healthcare sectors. It was founded in 1973 and is based in London, England.
BioCapital Europe is a life sciences investment conference that offers VCs and institutional investors unique and timely access to biotech, medtech, and diagnostics companies from the Benelux and Europe. It is based in Amsterdam, Netherlands.
Syncona Partners (LON: SYNC) is an investment company. The company offers services that include founding, building, and funding companies. It makes investments in life sciences companies including gene therapy, cell therapy, biologics, and small molecule fields. The company was founded in 2012 and is based in London, U.K.
Gershon Capital is an evergreen Swiss healthcare venture fund and hedge fund. It provides capital and strategic guidance for emerging life science companies with strong commercial potential in biotechnology, medical devices, healthcare AI, wearable sensors, and health and wellness. The company was founded in 2009 and is based in Switzerland.